

Ref. No: 1800
Date: 03/06/25
Subject: Dermatology and respiratory medicine

REQUEST

How many patients were treated in May 2025 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Lebrikizumab (Ebglyss)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)
- Nemolizumab (Nemluvio)

How many patients were treated in May 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

RESPONSE

How many patients were treated in May 2025 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo) **<5**
- Baricitinib (Olumiant) **12**

- Dupilumab (Dupixent) **43**
- Lebrikizumab (Ebglyss) **<5**
- Omalizumab (Xolair) **17**
- Tralokinumab (Adtralza) **<5**
- Upadacitinib (Rinvoq) **8**
- Nemolizumab (Nemluvio) **0**

How many patients were treated in May 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra) **0**
- Dupilumab (Dupixent) **0**
- Mepolizumab (Nucala) **0**
- Omalizumab (Xolair) **6**
- Reslizumab (Cinqaero) **0**
- Tezepelumab (Tezspire) **0**

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.